Tabula Rasa HealthCare (TRHC) Reports Q1 Revenues Beat; Offers 2Q & FY21 Revenues Outlook

Tabula Rasa HealthCare (NASDAQ: TRHC) reported Q1 revenue for the quarter came in at $80.5 million versus the consensus estimate of $76.15 million.

"I am pleased with the solid start to 2021 with first quarter revenue at the high end of our guidance range. We had an eventful quarter with a number of notable developments to start the year including: 1) a faster-than-expected return to historical PACE enrollment growth rates in March, which has continued into the second quarter of 2021; 2) a flurry of governmental policy activity at the federal level such as the PACE Plus Act that could exponentially expand the size of the PACE market; and 3) a publication in a peer-reviewed journal of an important study, with several more in the pipeline, which further validates and reinforces the strong outcomes and ROI associated with our MedWise® science," said Calvin H. Knowlton, PhD, TRHC's Chief Executive Officer, Chairman and Founder.

GUIDANCE:

Tabula Rasa HealthCare sees Q2 2021 revenue of $80.5-82.5 million, versus the consensus of $81.62 million.

Tabula Rasa HealthCare sees FY2021 revenue of $336-356 million, versus the consensus of $341.73 million.

For earnings history and earnings-related data on Tabula Rasa HealthCare (TRHC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Reading (RDI) Tops Q2 EPS by 4c